Clinical management of metastatic colorectal cancer in the era of precision medicine
F Ciardiello, D Ciardiello, G Martini… - CA: a cancer journal …, 2022 - Wiley Online Library
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
[HTML][HTML] The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges
Medical imaging can assess the tumor and its environment in their entirety, which makes it
suitable for monitoring the temporal and spatial characteristics of the tumor. Progress in …
suitable for monitoring the temporal and spatial characteristics of the tumor. Progress in …
Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer
The consensus molecular subtype (CMS) classification of colorectal cancer is based on bulk
transcriptomics. The underlying epithelial cell diversity remains unclear. We analyzed …
transcriptomics. The underlying epithelial cell diversity remains unclear. We analyzed …
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical
efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack …
efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack …
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and …
J Tabernero, A Grothey, E Van Cutsem… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF …
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF …
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
PURPOSE BRAF V600E mutations are rarely associated with objective responses to the
BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of …
BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of …
Biomarker-guided therapy for colorectal cancer: strength in complexity
The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …
[HTML][HTML] Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines
Background Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the
United States and worldwide, despite recent improvements in cancer management. CRC …
United States and worldwide, despite recent improvements in cancer management. CRC …
Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells
U Testa, E Pelosi, G Castelli - Medical Sciences, 2018 - mdpi.com
Colon cancer is the third most common cancer worldwide. Most colorectal cancer
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …